person · Reporting owner

Cox Troy

Disclosed activity across 7 companies

Tapewire entity: 28187
SEC CIK: 0001696923

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
MapLight Therapeutics, Inc.MPLT · Entity 5316	Director	July 28, 2026	July 29, 2026
SOPHiA GENETICS SASOPH · Entity 5228	Director	June 18, 2026	June 22, 2026
STANDARD BIOTOOLS INC.LAB · Entity 6116	Director	June 18, 2026	June 23, 2026
Zymeworks BC Inc.ZYME · Entity 12038	Director	May 06, 2021	May 07, 2021
Zymeworks Inc.ZYME · Entity 4458	Director	December 10, 2024	December 12, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MapLight Therapeutics, Inc.

Report date July 28, 2026 · Filed July 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Voting Common StockSEC Table I · non-derivative	IndirectBy trust	15,620	Reported balance After 2026-07-28 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-07-28 · Purchase · Acquired 15,620 · Balance 15,620 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.305 to $9.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: The shares are held by the Troy M Cox & Adeo C Alday JT Revocable Trust dtd 5/28/25, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
Voting Common StockSEC Table I · non-derivative	Direct	7,864	Reported balance Holding disclosure · report date 2026-07-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,864

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.305 to $9.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The shares are held by the Troy M Cox & Adeo C Alday JT Revocable Trust dtd 5/28/25, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.

SOPHiA GENETICS SA

Report date June 18, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	328,743	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Grant · Acquired 19,724 · Balance 328,743 F1: Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2036-06-18	Direct	252,809	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Grant · Acquired 28,818 · Balance 252,809 F2: The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

F2: The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

STANDARD BIOTOOLS INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	475,702	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Grant · Acquired 99,116 · Balance 475,702 F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2036-06-18	Direct	175,923	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Grant · Acquired 175,923 · Balance 175,923 F2: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

F2: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Zymeworks BC Inc.

Report date May 06, 2021 · Filed May 07, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05	Direct	9,000	Reported balance After 2021-05-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.

Zymeworks Inc.

Report date December 10, 2024 · Filed December 12, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.06 · Expires 2034-12-09	Direct	31,000	Reported balance After 2024-12-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-12-10 · Grant · Acquired 31,000 · Balance 31,000 F1: Stock options vest on date of next annual general meeting following grant date of December 10, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Stock options vest on date of next annual general meeting following grant date of December 10, 2024.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Foundation Medicine, Inc.

Report date July 31, 2018 · Filed August 02, 2018

Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-07-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-07-31 · Other · Disposed 35,221 · Balance 206,847 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Row 2 · 2018-07-31 · Other · Disposed 206,847 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.

F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.

F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.

SomaLogic, Inc.

Report date January 05, 2024 · Filed January 10, 2024

Section 16 reporting ended · disclosed 2024-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-01-05 transaction · row 1 1 source row Row 1 · 2024-01-05 · Disposition to issuer · Disposed 78,430 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2031-10-26	Direct	Reported balance After 2024-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-01-05 · Disposition to issuer · Disposed 46,705 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2032-02-29	Direct	Reported balance After 2024-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-01-05 · Disposition to issuer · Disposed 20,600 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5: The option is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.88 · Expires 2032-10-16	Direct	Reported balance After 2024-01-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-05 · Disposition to issuer · Disposed 885,416 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6: The option vested as to 1/3rd of the total grant on October 17, 2023, and thereafter 1/24th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-03-16	Direct	Reported balance After 2024-01-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-01-05 · Disposition to issuer · Disposed 171,500 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F7: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Warrant to purchase common stock (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-01	Direct	Reported balance After 2024-01-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-05 · Disposition to issuer · Disposed 166,666 · Balance 0 F9: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio. F8: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-05 · Disposition to issuer · Disposed 28,500 · Balance 0 F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F11: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.

F3: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.

F5: The option is fully vested and exercisable.

F6: The option vested as to 1/3rd of the total grant on October 17, 2023, and thereafter 1/24th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F7: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F8: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023.

F9: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio.

F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.

F11: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date.

F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 28, 2026 Filed Jul 29, 2026 01:14 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	PurchaseVoting Common Stock	15,620	$9.52	$148,702.40	Disclosure SEC source: 0001696923-26-000007 · form4-07292026_010736.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 15,620 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.305 to $9.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held by the Troy M Cox & Adeo C Alday JT Revocable Trust dtd 5/28/25, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power. Read SEC document
June 23, 2026 Filed Jun 25, 2026 22:04 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	GrantStock Option (right to buy) · Derivative	29,804	$0.00 Strike: $28.64	$0.00	Disclosure SEC source: 0001696923-26-000005 · form4-06252026_100620.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,804 Underlying: Voting Common Stock · 29,804 shares Expires 2036-06-22 F3 · derivative.exercise_date: Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Read SEC document
June 23, 2026 Filed Jun 25, 2026 22:04 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	GrantVoting Common Stock	7,864	$0.00	$0.00	Disclosure SEC source: 0001696923-26-000005 · form4-06252026_100620.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,864 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document
June 18, 2026 Filed Jun 22, 2026 20:01 UTC	SOPHiA GENETICS SA SOPH · Entity 5228	GrantShare Option (Right to Buy) · Derivative	28,818	$5.46 Strike: $5.46	$157,346.28	Disclosure SEC source: 0001840706-26-000224 · wk-form4_1782158508.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,809 Underlying: Ordinary Shares · 28,818 shares Expires 2036-06-18 F2 · derivative.exercise_date: The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date. Read SEC document
June 18, 2026 Filed Jun 22, 2026 20:01 UTC	SOPHiA GENETICS SA SOPH · Entity 5228	GrantOrdinary Shares	19,724	$5.46	$107,693.04	Disclosure SEC source: 0001840706-26-000224 · wk-form4_1782158508.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,743 F1 · shares: Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:41 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	175,923	$0.00 Strike: $0.83	$0.00	Disclosure SEC source: 0001193125-26-279827 · ownership.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,923 Underlying: Common Stock · 175,923 shares Expires 2036-06-18 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:41 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	99,116	$0.00	$0.00	Disclosure SEC source: 0001193125-26-279827 · ownership.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,702 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document
February 26, 2026 Filed Mar 3, 2026 00:32 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	57,264	$1.17	$66,998.88	Disclosure SEC source: 0001193125-26-086158 · ownership.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,586 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2026, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $67,000 in cash compensation for services as a board member. Read SEC document
June 20, 2025 Filed Jun 24, 2025 23:00 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	125,660	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0000950170-25-089657 · ownership.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,660 Underlying: Common Stock · 125,660 shares Expires 2035-06-20 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 20, 2025 Filed Jun 24, 2025 23:00 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	94,592	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089657 · ownership.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,412 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:51 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	62,910	$1.07	$66,999.15	Disclosure SEC source: 0000950170-25-032552 · ownership.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,730 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date. F2 · price: The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $67,000 in cash compensation for services as a board member. Read SEC document
December 10, 2024 Filed Dec 12, 2024 22:52 UTC	Zymeworks Inc. ZYME · Entity 4458	GrantStock Option (Right to Buy) · Derivative	31,000	$0.00 Strike: $13.06	$0.00	Disclosure SEC source: 0000950170-24-135922 · ownership.xml · derivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 10, 2024. Read SEC document
June 28, 2024 Filed Jul 2, 2024 21:19 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	72,213	$0.00 Strike: $1.77	$0.00	Disclosure SEC source: 0000950170-24-080745 · ownership.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,213 Underlying: Common Stock · 72,213 shares Expires 2034-06-28 F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 28, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 28, 2024 Filed Jul 2, 2024 21:19 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	43,128	$0.00	$0.00	Disclosure SEC source: 0000950170-24-080745 · ownership.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,820 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. F2 · balance_after: The Reporting Person declined and forfeited the 79,412 RSUs previously granted to the Reporting Person on January 5, 2024 in connection with the transactions contemplated by the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc., Martis Merger Sub, Inc. and SomaLogic, Inc. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantWarrant to purchase Common Stock (Right to buy) · Derivative	184,999	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 8 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,999 Underlying: Common Stock · 184,999 shares Expires 2026-09-01 F10 · price: Pursuant to the Merger Agreement, each warrant to purchase SomaLogic common stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of common stock of the Company equal to multiplying the number of shares of common stock of SomaLogic subject to such warrant by the Exchange Ratio. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	190,365	Not disclosed Strike: $2.08	Not disclosed	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 7 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,365 Underlying: Common Stock · 190,365 shares Expires 2033-03-16 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F9 · derivative.exercise_date: 25% of the shares underlying the option vest on March 17, 2024, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	982,811	Not disclosed Strike: $2.60	Not disclosed	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 6 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 982,811 Underlying: Common Stock · 928,811 shares Expires 2032-10-16 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F8 · derivative.exercise_date: One third of the shares underlying the option vested on October 17, 2023, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	22,866	Not disclosed Strike: $8.18	Not disclosed	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 5 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,866 Underlying: Common Stock · 22,866 shares Expires 2032-02-29 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F7 · derivative.exercise_date: This option is fully vested and currently exercisable. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	51,842	Not disclosed Strike: $10.68	Not disclosed	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 4 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,842 Underlying: Common Stock · 51,842 shares Expires 2031-10-26 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F5 · derivative.exercise_date: 25% of the shares underlying the option vested on October 27, 2022, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	31,635	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · nonDerivative · entry 3 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,104 F3 · shares: Represents RSUs that vest in four equal annual installments beginning March 17, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. F4 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of SomaLogic common stock (a "SomaLogic RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of common stock of the Company equal to the to the product of (i) the number of shares subject to such SomaLogic RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Company common stock rounded to the next nearest whole share. Except as noted above, each assumed SomaLogic RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic RSU immediately prior to the Effective Time. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	79,412	$0.00	$0.00	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · nonDerivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,469 F2 · shares: Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning January 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:05 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	87,057	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,057 F1 · shares: Received in exchange for 78,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). F1 · price: Received in exchange for 78,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:30 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit · Derivative	28,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001316 · doc4.xml · derivative · entry 7 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,500 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F11 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date. F11 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:30 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerWarrant to purchase common stock (Right to buy) · Derivative	166,666	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001209191-24-001316 · doc4.xml · derivative · entry 6 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,666 shares Expires 2026-09-01 F9 · price: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio. F8 · derivative.exercise_date: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:30 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	171,500	Not disclosed Strike: $2.30	Not disclosed	Disclosure SEC source: 0001209191-24-001316 · doc4.xml · derivative · entry 5 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 171,500 shares Expires 2033-03-16 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F7 · derivative.exercise_date: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:30 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	885,416	Not disclosed Strike: $2.88	Not disclosed	Disclosure SEC source: 0001209191-24-001316 · doc4.xml · derivative · entry 4 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 885,416 shares Expires 2032-10-16 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6 · derivative.exercise_date: The option vested as to 1/3rd of the total grant on October 17, 2023, and thereafter 1/24th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:30 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	20,600	Not disclosed Strike: $9.08	Not disclosed	Disclosure SEC source: 0001209191-24-001316 · doc4.xml · derivative · entry 3 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,600 shares Expires 2032-02-29 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:30 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	46,705	Not disclosed Strike: $11.85	Not disclosed	Disclosure SEC source: 0001209191-24-001316 · doc4.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,705 shares Expires 2031-10-26 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3 · derivative.exercise_date: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:30 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerCommon Stock	78,430	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001316 · doc4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. Read SEC document
December 07, 2023 Filed Dec 8, 2023 22:26 UTC	Zymeworks Inc. ZYME · Entity 4458	GrantStock Option (Right to Buy) · Derivative	37,000	$0.00 Strike: $9.55	$0.00	Disclosure SEC source: 0000950170-23-069115 · ownership.xml · derivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. Read SEC document
March 17, 2023 Filed Mar 22, 2023 10:02 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (right to buy) · Derivative	171,500	$0.00 Strike: $2.30	$0.00	Disclosure SEC source: 0001213900-23-021842 · ownership.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,500 Underlying: Common Stock, par value $0.0001 · 171,500 shares Expires 2033-03-16 F1 · shares: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
March 17, 2023 Filed Mar 22, 2023 10:02 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantCommon Stock	28,500	$0.00	$0.00	Disclosure SEC source: 0001213900-23-021842 · ownership.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,930 Read SEC document
December 21, 2022 Filed Dec 24, 2022 00:00 UTC	Zymeworks Inc. ZYME · Entity 4458	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.75	$0.00	Disclosure SEC source: 0000899243-22-039325 · doc4.xml · derivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. Read SEC document
October 17, 2022 Filed Oct 18, 2022 21:52 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (right to buy) · Derivative	885,416	$0.00 Strike: $2.88	$0.00	Disclosure SEC source: 0001213900-22-064754 · ownership.xml · derivative · entry 1 Cox Troy · CIK 0001696923 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,416 Underlying: Common Stock, par value $0.0001 · 885,416 shares Expires 2032-10-16 F1 · derivative.exercise_date: One third of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of the following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
March 01, 2022 Filed Mar 4, 2022 02:07 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (right to buy) · Derivative	20,600	$0.00 Strike: $9.08	$0.00	Disclosure SEC source: 0001062993-22-006750 · form4.xml · derivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock, par value $0.0001 · 20,600 shares Expires 2032-02-29 F1 · shares: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
March 01, 2022 Filed Mar 4, 2022 02:07 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantCommon Stock	3,430	$0.00	$0.00	Disclosure SEC source: 0001062993-22-006750 · form4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,430 Read SEC document
October 27, 2021 Filed Dec 13, 2021 21:55 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (right to buy) · Derivative	46,705	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0001062993-21-012776 · form4.xml · derivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,705 Underlying: Common Stock, par value $0.0001 · 46,705 shares Expires 2031-10-26 F1 · derivative.exercise_date: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
September 01, 2021 Filed Sep 4, 2021 00:30 UTC	SomaLogic, Inc. SLGCW · Entity 95310	Exercise / conversionClass B Common Stock · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001213900-21-046744 · ownership.xml · derivative · entry 4 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. Read SEC document
September 01, 2021 Filed Sep 4, 2021 00:30 UTC	SomaLogic, Inc. SLGCW · Entity 95310	GrantWarrants to purchase Class A Common Stock (right to buy) · Derivative	166,666	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001213900-21-046744 · ownership.xml · derivative · entry 3 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Class A Common Stock · 166,666 shares Expires 2026-09-01 F2 · kind: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. F2 · price: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. Read SEC document
September 01, 2021 Filed Sep 4, 2021 00:30 UTC	SomaLogic, Inc. SLGCW · Entity 95310	GrantClass A Common Stock	50,000	$10.00	$500,000.00	Disclosure SEC source: 0001213900-21-046744 · ownership.xml · nonDerivative · entry 2 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Read SEC document
September 01, 2021 Filed Sep 4, 2021 00:30 UTC	SomaLogic, Inc. SLGCW · Entity 95310	OtherClass A Common Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001213900-21-046744 · ownership.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. Read SEC document
May 06, 2021 Filed May 7, 2021 20:45 UTC	Zymeworks BC Inc. ZYME · Entity 12038	GrantStock Option (Right to Buy) · Derivative	9,000	$0.00 Strike: $29.49	$0.00	Disclosure SEC source: 0000899243-21-018764 · doc4.xml · derivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2031-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. Read SEC document
May 08, 2020 Filed May 12, 2020 06:30 UTC	Zymeworks BC Inc. ZYME · Entity 12038	GrantStock Option (Right to Buy) · Derivative	9,000	$0.00 Strike: $35.49	$0.00	Disclosure SEC source: 0000899243-20-012774 · doc4.xml · derivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-05-07 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 8, 2020. Read SEC document
January 27, 2020 Filed Jan 28, 2020 20:10 UTC	Zymeworks BC Inc. ZYME · Entity 12038	PurchaseCommon Shares	7,500	$46.50	$348,750.00	Disclosure SEC source: 0000899243-20-002248 · doc4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Purchased in Issuer's underwritten public offering that closed on January 27, 2020. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	206,847	$137.00	$28,338,039.00	Disclosure SEC source: 0001209191-18-044919 · doc4.xml · nonDerivative · entry 2 Cox Troy · CIK 0001696923 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3 · shares: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	35,221	$137.00	$4,825,277.00	Disclosure SEC source: 0001209191-18-044919 · doc4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,847 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Read SEC document
July 02, 2018 Filed Jul 5, 2018 16:06 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,402	$136.66	$191,597.32	Disclosure SEC source: 0001209191-18-041541 · doc4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,068 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2018 in Table I of the Form 4 filed on April 3, 2018. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
May 16, 2018 Filed May 17, 2018 16:13 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	2,157	$77.10	$166,304.70	Disclosure SEC source: 0001209191-18-030880 · doc4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,470 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2017. The sale of a portion of these shares were effected to cover tax liabilities of the reporting person in connection with the vesting and release of restricted stock units. Read SEC document
May 07, 2018 Filed May 9, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	7,063	$70.01	$494,480.63	Disclosure SEC source: 0001209191-18-028837 · doc4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,627 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on May 6, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. Read SEC document
April 01, 2018 Filed Apr 3, 2018 16:09 UTC	Foundation Medicine, Inc. FMI · Entity 164565	GrantCommon Stock	37,357	$78.75	$2,941,863.75	Disclosure SEC source: 0001209191-18-022877 · doc4.xml · nonDerivative · entry 1 Cox Troy · CIK 0001696923 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,690 F1 · shares: Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.